68
Views
3
CrossRef citations to date
0
Altmetric
Commentary

Long dosing intervals in the treatment of postmenopausal osteoporosis

Pages 2617-2625 | Accepted 16 Aug 2007, Published online: 13 Sep 2007
 

ABSTRACT

Background: Osteoporosis is a common disease associ­ated with diminished bone strength and increased risk of fracture. With the aging of the population, the number of people with osteoporosis, particularly postmenopausal women, is expected to increase. There are excellent tools for diagnosing osteoporosis and widely available treat­ments that are safe and effective. Nevertheless, osteo­porosis is underdiagnosed and undertreated. Even among those who are diagnosed and treated, widespread non­adherence with treatment regimens undermines the efficacy of osteoporosis therapy.

Purpose: To examine the pharmacological options for the treatment of postmenopausal osteoporosis and the influence of extended dosing intervals upon outcomes, medication adherence, and patient preference.

Methods: A Medline and Cochrane Review database search was conducted for appropriate clinical trials, meta-analyses, and systematic reviews published between 1987 and 2007.

Findings: The causes of nonadherence include poor understanding of the consequences of a silent disease, concern regarding potential side-effects of medications, the inconvenience associated with administration of some osteoporosis medications, and medication costs. The recent development of effective oral and injectable osteo­porosis medications that can be given with long dosing intervals may improve patient adherence. Less frequent dosing lessens the inconvenience of administration, and dosing by injection assures that the medication is 100% bioavailable. Osteoporosis patients have shown a preference for monthly bisphosphonate dosing compared with weekly dosing.

Conclusion: Enhanced adherence with new dosing regimens can be expected to improve treatment efficacy, reduce fracture risk, and lessen the burden of osteo­porosis on patients and society. Further study is required to fully elucidate the relationship between extended dosing, adherence, and positive outcomes.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.